{"id":"NCT03959241","sponsor":"Medical College of Wisconsin","briefTitle":"TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)","officialTitle":"A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 1703; Progress III); Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (BMT CTN 1801; Mi-Immune)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-25","primaryCompletion":"2022-09-19","completion":"2022-09-19","firstPosted":"2019-05-22","resultsPosted":"2024-01-12","lastUpdate":"2024-04-04"},"enrollment":431,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Acute Leukemia","Chronic Myelogenous Leukemia (CML)","Myelodysplasia","Lymphoma"],"interventions":[{"type":"PROCEDURE","name":"Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate","otherNames":["HSCT"]},{"type":"DRUG","name":"Tacrolimus","otherNames":["Prograf速","FK506"]},{"type":"DRUG","name":"Methotrexate","otherNames":["MTX"]},{"type":"PROCEDURE","name":"Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide","otherNames":["HSCT"]},{"type":"DRUG","name":"Tacrolimus","otherNames":["Prograf速","FK506"]},{"type":"DRUG","name":"Mycophenolate Mofetil","otherNames":["CellCept速","MMF"]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":["Cytoxan速"]}],"arms":[{"label":"Tacrolimus/Methotrexate","type":"ACTIVE_COMPARATOR"},{"label":"Tacrolimus/MMF/PTCY","type":"EXPERIMENTAL"}],"summary":"1703: The study is designed as a randomized, phase III, multicenter trial comparing two acute graft-versus-host disease (aGVHD) prophylaxis regimens: tacrolimus/methotrexate (Tac/MTX) versus post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil (PTCy/Tac/MMF) in the setting of reduced intensity conditioning (RIC) allogeneic peripheral blood stem cell (PBSC) transplantation.\n\n1801: The goal of this protocol is to test the primary hypothesis that the engraftment stool microbiome diversity predicts one-year non-relapse mortality in patients undergoing reduced intensity allogeneic HCT.","primaryOutcome":{"measure":"Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) at One Year","timeFrame":"1 year post randomization","effectByArm":[{"arm":"PTCY/Tacrolimus/MMF","deltaMin":52.3,"sd":null},{"arm":"Tacrolimus/Methotrexate","deltaMin":35.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":39,"countries":["United States"]},"refs":{"pmids":["37342922","40305657","39752608"],"seeAlso":["https://bmtctn.net//"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":208},"commonTop":["Grades 3-5 Cardiac Disorders","Grades 3-5 GI Disorders","Grades 3-5 General Disorders","Grades 3-5 Respiratory, Thoracic and Mediastinal Disorders","Grades 3-5 Hepatic Disorders"]}}